Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Colapietro, Alessandro"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-9 z 9
    Tytuł:
    ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.
    Autorzy:
    Gravina GL; Department of Biotechnological and Applied Clinical Sciences, Division of Radiation Oncology, University of L'Aquila, 67100 L'Aquila, Italy.
    Colapietro A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.
    Mancini A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.
    Rossetti A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.
    Martellucci S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Cellular Pathology, University of L'Aquila, 67100 L'Aquila, Italy.; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.
    Ventura L; Division of Pathology, San Salvatore Hospital, 67100 L'Aquila, Italy.
    Di Franco M; Division of Pathology, San Salvatore Hospital, 67100 L'Aquila, Italy.
    Marampon F; Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00100 Rome, Italy.
    Mattei V; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.
    Biordi LA; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Medical Oncology, University of L'Aquila, 67100 L'Aquila, Italy.
    Otterlei M; APIM Therapeutics A/S, N-7100 Rissa, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), N-7006 Trondheim, Norway.
    Festuccia C; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Jan 07; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 07.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.
    Autorzy:
    Colapietro A; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Rossetti A; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Mancini A; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Martellucci S; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.; Laboratory of Vascular Biology and Stem Cells, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Ocone G; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Pulcini F; Laboratory of Vascular Biology and Stem Cells, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Biordi L; Laboratory of Medical Oncology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Cristiano L; Department of Clinical Medicine, Public Health, Division of Human Anatomy, University of L'Aquila, 67100 L'Aquila, Italy.
    Mattei V; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.
    Delle Monache S; Laboratory of Vascular Biology and Stem Cells, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Marampon F; Department of Radiological, Oncological and Pathological Sciences, La Sapienza University of Rome, 00185 Rome, Italy.
    Gravina GL; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, Division of Radiotherapy, University of L'Aquila, 67100 L'Aquila, Italy.
    Festuccia C; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Pokaż więcej
    Źródło:
    Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2021 Oct 26; Vol. 14 (11). Date of Electronic Publication: 2021 Oct 26.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
    Autorzy:
    Mattei V; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.; Department of Experimental Medicine, Sapienza University, 00161 Rome, Italy.
    Santilli F; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.; Department of Experimental Medicine, Sapienza University, 00161 Rome, Italy.
    Martellucci S; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Delle Monache S; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Fabrizi J; Biomedicine and Advanced Technologies Rieti Center, Sabina Universitas, 02100 Rieti, Italy.
    Colapietro A; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Angelucci A; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Festuccia C; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
    Pokaż więcej
    Źródło:
    International journal of molecular sciences [Int J Mol Sci] 2021 Apr 08; Vol. 22 (8). Date of Electronic Publication: 2021 Apr 08.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Drug Resistance, Neoplasm*/genetics
    Antineoplastic Agents/*pharmacology
    Brain Neoplasms/*metabolism
    Glioblastoma/*metabolism
    Neoplastic Stem Cells/*drug effects
    Neoplastic Stem Cells/*metabolism
    Animals ; Antineoplastic Agents/therapeutic use ; Biomarkers ; Brain Neoplasms/drug therapy ; Brain Neoplasms/etiology ; Brain Neoplasms/pathology ; Cell Differentiation ; Cell Self Renewal ; Disease Susceptibility ; Glioblastoma/drug therapy ; Glioblastoma/etiology ; Glioblastoma/pathology ; Humans ; Neoplastic Stem Cells/pathology ; Signal Transduction/drug effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo .
    Autorzy:
    Colapietro A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
    Gravina GL; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
    Petragnano F; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Pharmacology, University of L'Aquila, L'Aquila, Italy.
    Fasciani I; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Pharmacology, University of L'Aquila, L'Aquila, Italy.
    Scicchitano BM; Istituto di Istologia ed Embriologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Largo Francesco Vito 1-00168, Roma, Italy.
    Beirinckx F; Galapagos NV, Mechelen, Belgium.
    Pujuguet P; Galapagos SASU, Romainville, France.
    Saniere L; Galapagos SASU, Romainville, France.
    Van der Aar E; Galapagos NV, Mechelen, Belgium.
    Musio D; Department of Radiotherapy, Hospital Umberto I 'Sapienza', University of Rome, Rome, Italy.
    De Felice F; Department of Radiotherapy, Hospital Umberto I 'Sapienza', University of Rome, Rome, Italy.
    Mattei V; Laboratory of Experimental Medicine and Enviromental Pathology, University Hub 'Sabina Univeristas', Rieti, Italy.
    Martellucci S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.; Laboratory of Experimental Medicine and Enviromental Pathology, University Hub 'Sabina Univeristas', Rieti, Italy.
    Maggio R; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Pharmacology, University of L'Aquila, L'Aquila, Italy.
    Tombolini V; Department of Radiotherapy, Hospital Umberto I 'Sapienza', University of Rome, Rome, Italy.
    Festuccia C; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy.
    Marampon F; Department of Radiotherapy, Hospital Umberto I 'Sapienza', University of Rome, Rome, Italy.
    Pokaż więcej
    Źródło:
    Journal of oncology [J Oncol] 2020 Feb 27; Vol. 2020, pp. 9342732. Date of Electronic Publication: 2020 Feb 27 (Print Publication: 2020).
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
    Autorzy:
    Festuccia C; Department of Biotechnological and Applied Clinical Sciences, laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.
    Mancini A; Department of Biotechnological and Applied Clinical Sciences, laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.; Multi-Factorial Disease and Complex Phenotype Research Area, Bambino Gesù Children's Hospital, IRCCS, Viale di San Paolo 15, 00146 Rome, Italy.
    Gravina GL; Department of Biotechnological and Applied Clinical Sciences, laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, Division of Radiation Oncology, University of L'Aquila, 67100 L'Aquila, Italy.
    Colapietro A; Department of Biotechnological and Applied Clinical Sciences, laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy.
    Vetuschi A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Human Anatomy, University of L'Aquila, 67100 L'Aquila, Italy.
    Pompili S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Human Anatomy, University of L'Aquila, 67100 L'Aquila, Italy.
    Ventura L; Pathology Department, San Salvatore Hospital, L'Aquila 67100, Italy.
    Delle Monache S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Applied Biology, University of L'Aquila, 67100 L'Aquila, Italy.
    Iorio R; Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila 67100, Italy.
    Del Fattore A; Multi-Factorial Disease and Complex Phenotype Research Area, Bambino Gesù Children's Hospital, IRCCS, Viale di San Paolo 15, 00146 Rome, Italy.
    Fogler W; GlycoMimetics Inc. Gaithersburg, MD 20850, USA.
    Magnani J; GlycoMimetics Inc. Gaithersburg, MD 20850, USA.
    Pokaż więcej
    Źródło:
    Cells [Cells] 2019 Dec 20; Vol. 9 (1). Date of Electronic Publication: 2019 Dec 20.
    Typ publikacji:
    Comparative Study; Journal Article
    MeSH Terms:
    Bone Neoplasms/*drug therapy
    Bone Neoplasms/*secondary
    Docetaxel/*administration & dosage
    Prostatic Neoplasms, Castration-Resistant/*drug therapy
    Small Molecule Libraries/*administration & dosage
    Animals ; Bone Neoplasms/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Docetaxel/pharmacology ; Drug Synergism ; E-Selectin/antagonists & inhibitors ; Glycolipids/administration & dosage ; Glycolipids/pharmacology ; Humans ; Male ; Mice ; PC-3 Cells ; Peptides/administration & dosage ; Peptides/pharmacology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Receptors, CXCR4/antagonists & inhibitors ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology ; Xenograft Model Antitumor Assays
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models.
    Autorzy:
    Gravina GL; Department of Biotechnological and Applied Clinical Sciences, Division of Radiation Oncology, University of L'Aquila, 67100 L'Aquila, Italy. .
    Mancini A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy. mancio_.
    Colapietro A; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, 67100 L'Aquila, Italy. .
    Delle Monache S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Cellular Biology, University of L'Aquila, 67100 L'Aquila, Italy. .
    Sferra R; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Human Anatomy, University of L'Aquila, 67100 L'Aquila, Italy. .
    Pompili S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Human Anatomy, University of L'Aquila, 67100 L'Aquila, Italy. .
    Vitale F; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Neurophysiology, University of L'Aquila, 67100 L'Aquila, Italy. .
    Martellucci S; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Cellular Biology, University of L'Aquila, 67100 L'Aquila, Italy. .; Laboratory of Experimental Medicine and Environmental Pathology, University Hub 'Sabina Universitas', 02100 Rieti, Italy. .
    Marampon F; Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00118 Rome, Italy. .
    Mattei V; Laboratory of Experimental Medicine and Environmental Pathology, University Hub 'Sabina Universitas', 02100 Rieti, Italy. .
    Biordi L; Department of Biotechnological and Applied Clinical Sciences, Laboratory of Experimental Oncology, University of L'Aquila, 67100 L'Aquila, Italy. .
    Sherris D; Sherris Pharma Partners, Jamaica Plain, MA 02130, USA. .
    Festuccia C; Department of Biotechnological and Applied Clinical Sciences, Division of Radiation Oncology, University of L'Aquila, 67100 L'Aquila, Italy. .
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2019 Oct 21; Vol. 11 (10). Date of Electronic Publication: 2019 Oct 21.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models.
    Autorzy:
    Gravina GL; Division of Radiation Oncology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. .
    Mancini A; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. mancio_.
    Colapietro A; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. .
    Delle Monache S; Laboratory of cellular pathology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 (Coppito II), 67100 L'Aquila, Italy. .
    Sferra R; Laboratory of Human Anatomy; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. .
    Vitale F; Laboratory of Neurophysiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. .
    Cristiano L; Department of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. .
    Martellucci S; Laboratory of cellular pathology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 (Coppito II), 67100 L'Aquila, Italy. .; Laboratory of Experimental Medicine and Environmental Pathology, University Hub 'Sabina Universitas', 02100 Rieti, Italy. .
    Marampon F; Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Rome, Italy. .
    Mattei V; Laboratory of Experimental Medicine and Environmental Pathology, University Hub 'Sabina Universitas', 02100 Rieti, Italy. .
    Beirinckx F; Galapagos NV, Industriepark Mechelen Noord, General De Wittelaan L11 A3, 2880 Mechelen, Belgium. .
    Pujuguet P; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France. .
    Saniere L; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France. .
    Lorenzon G; Galapagos NV, Industriepark Mechelen Noord, General De Wittelaan L11 A3, 2880 Mechelen, Belgium. .
    van der Aar E; Galapagos NV, Industriepark Mechelen Noord, General De Wittelaan L11 A3, 2880 Mechelen, Belgium. .
    Festuccia C; Laboratory of Radiobiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio (Coppito II), 67100 L'Aquila, Italy. .
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2019 Mar 13; Vol. 11 (3). Date of Electronic Publication: 2019 Mar 13.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
    Autorzy:
    Festuccia C; Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. .
    Mancini A; Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Colapietro A; Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Gravina GL; Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.; Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Vitale F; Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Marampon F; Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Delle Monache S; Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Pompili S; Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Cristiano L; Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
    Vetuschi A; Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy.
    Tombolini V; Division of Radiotherapy, Department of Experimental Medicine, University of Rome 'La Sapienza', Rome, Italy.
    Chen Y; Northlake International LLC, Pleasanton, CA, USA.
    Mehrling T; Mundipharma-EDO GmbH, Basel, Switzerland.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2018 Feb 27; Vol. 11 (1), pp. 32. Date of Electronic Publication: 2018 Feb 27.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents, Alkylating/*therapeutic use
    Benzimidazoles/*therapeutic use
    Brain Neoplasms/*drug therapy
    Brain Neoplasms/*radiotherapy
    Glioblastoma/*drug therapy
    Glioblastoma/*radiotherapy
    Histone Deacetylase Inhibitors/*therapeutic use
    Animals ; Antineoplastic Agents, Alkylating/pharmacology ; Bendamustine Hydrochloride/pharmacology ; Bendamustine Hydrochloride/therapeutic use ; Benzimidazoles/pharmacology ; Brain Neoplasms/pathology ; Cell Line, Tumor ; Female ; Glioblastoma/pathology ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Mice ; Vorinostat/pharmacology ; Vorinostat/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
    Autorzy:
    Gravina GL; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Mancini A; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Marampon F; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Colapietro A; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Delle Monache S; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Sferra R; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Vitale F; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy.
    Richardson PJ; Proximagen Ltd., Babraham Research Campus, Cambridge, CB22 3AT, UK.
    Patient L; Proximagen Ltd., Babraham Research Campus, Cambridge, CB22 3AT, UK.
    Burbidge S; Proximagen Ltd., Babraham Research Campus, Cambridge, CB22 3AT, UK.
    Festuccia C; Department of Biotechnological and Applied Clinical Sciences, Neurobiology Laboratory, University of L'Aquila, Via vetoios snc, Coppito II, L'Aquila, Italy. .
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2017 Jan 05; Vol. 10 (1), pp. 5. Date of Electronic Publication: 2017 Jan 05.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Bevacizumab/*therapeutic use
    Brain/*drug effects
    Glioblastoma/*drug therapy
    Indoles/*therapeutic use
    Pyrroles/*therapeutic use
    Receptors, CXCR4/*antagonists & inhibitors
    Angiogenesis Inhibitors ; Animals ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Bevacizumab/pharmacology ; Brain/metabolism ; Brain Neoplasms/drug therapy ; Cell Line, Tumor ; Drug Evaluation, Preclinical ; Drug Interactions ; Drug Synergism ; Heterografts ; Humans ; Indoles/pharmacology ; Mice ; Pyrroles/pharmacology ; Sunitinib
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-9 z 9

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies